Novel GCGR/GLP-1R dual agonist survodutide effectively reduces HbA1c and body weight in type 2 diabetes: Phase 2 trial
Germany: A recent study published in Diabetologia has shed light on survodutide dose-response effects on body weight and HbA1c reduction, compared with placebo and open-label semaglutide in patients with type 2 diabetes (T2D). Findings from the phase II randomized clinical trial showed a greater reduction in body weight and HbA1c levels after 16 weeks of […]